{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Consoli F"],"funding":["Novartis (Italy)"],"pagination":["4072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11640251"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(23)"],"pubmed_abstract":["<b>Background/Objective</b>: Dabrafenib and trametinib (D + T) have been approved for the treatment of stage III melanoma with BRAF V600E V600K mutations in an adjuvant setting, based on the results from the COMBI-AD trial. To provide early access to this combination therapy prior to its commercial availability in Italy, a Managed Access Program (MAP) was run in Italy from June 2018 to December 2019. <b>Methods</b>: The MADAM (Maximing ADjuvAnt MAP) study is an Italian retrospective-prospective observational study that included patients who received at least one dose of D + T through the MAP. The primary endpoints were relapse-free survival (RFS) and overall survival (OS). <b>Results</b>: This interim analysis presents findings after the first 24 months of follow-up. A total of 310 patient"],"journal":["Cancers"],"pubmed_title":["Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis."],"pmcid":["PMC11640251"],"funding_grant_id":["NA"],"pubmed_authors":["Morgese F","Tucci M","Pigozzo J","Consoli F","Simeone E","Quaglino P","Morelli MF","Marcon I","Valsecchi D","Tronconi MC","Merelli B","Del Vecchio M","Spagnolo F","Troiani T","Melotti B","Grosso F"],"additional_accession":[]},"is_claimable":false,"name":"Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.","description":"<b>Background/Objective</b>: Dabrafenib and trametinib (D + T) have been approved for the treatment of stage III melanoma with BRAF V600E V600K mutations in an adjuvant setting, based on the results from the COMBI-AD trial. To provide early access to this combination therapy prior to its commercial availability in Italy, a Managed Access Program (MAP) was run in Italy from June 2018 to December 2019. <b>Methods</b>: The MADAM (Maximing ADjuvAnt MAP) study is an Italian retrospective-prospective observational study that included patients who received at least one dose of D + T through the MAP. The primary endpoints were relapse-free survival (RFS) and overall survival (OS). <b>Results</b>: This interim analysis presents findings after the first 24 months of follow-up. A total of 310 patient","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-03T23:27:04.401Z","creation":"2025-04-03T23:27:04.401Z"},"accession":"S-EPMC11640251","cross_references":{"pubmed":["39682258"],"doi":["10.3390/cancers16234072"]}}